Zentalis

38 articles about Zentalis

• Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 01, 2023

  9/1/2023

  Zentalis® Pharmaceuticals, Inc. announced that on September 1, 2023, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 32,975 shares of the Company’s common stock to four newly hired employees.

• Zentalis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates

  8/9/2023

  Zentalis® Pharmaceuticals, Inc. today announced financial results for the quarter ended June 30, 2023, and highlighted recent corporate accomplishments.

• Zentalis Pharmaceuticals Appoints Kimberly Freeman as Chief Strategy Officer

  8/1/2023

  Zentalis ® Pharmaceuticals, Inc. today announced the appointment of Kimberly Freeman as Chief Strategy Officer. In this role, she will support and implement Zentalis’ long-term portfolio strategy.

• Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - August 01, 2023

  8/1/2023

  Zentalis® Pharmaceuticals, Inc. announced that on August 1, 2023, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 275,000 shares of the Company’s common stock to one newly hired employee.

• Zentalis Pharmaceuticals Announces Pricing of Underwritten Offering of Common Stock - June 15, 2023

  6/15/2023

  Zentalis® Pharmaceuticals, Inc. announced the pricing of an underwritten offering of 11,032,656 shares of its common stock at an offering price of $22.66 per share, for total gross proceeds of approximately $250.0 million, before deducting underwriting discounts and commissions and offering expenses payable by the Company.

• Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing

  6/6/2023

  Zentalis® Pharmaceuticals, Inc. announced the monotherapy recommended Phase 2 dose for azenosertib, the Company's potentially first-in-class WEE1 inhibitor.

• Zentalis Announces Presentation of Positive Phase 1b Data Demonstrating Durable Responses and Favorable Safety Profile of Azenosertib in Combination with Chemotherapy at the 2023 ASCO Annual Meeting

  5/25/2023

  Zentalis® Pharmaceuticals, Inc. announced positive data from the Phase 1b trial of azenosertib, the Company’s potentially first-in-class WEE1 inhibitor, in combination with chemotherapy in patients with platinum-resistant ovarian cancer.

• Zentalis to Host Investor Call to Provide Clinical Update with Safety, Pharmacology, and Efficacy Results for Azenosertib Monotherapy and Development Plans for Monotherapy and Chemotherapy Combinations

  5/23/2023

  Zentalis ® Pharmaceuticals, Inc. today announced that the Company will host an investor update call to share the safety and efficacy results from its ongoing monotherapy dose optimization Phase 1 study of azenosertib, its potentially first-in-class WEE1 inhibitor product candidate.

• Zentalis to present positive clinical data in ovarian cancer combining azenosertib and chemotherapy, including at the 2023 ASCO Annual Meeting

  4/26/2023

  Zentalis ® Pharmaceuticals, Inc. announced today that it will present positive clinical data from its Phase 1b trial investigating azenosertib in combination with chemotherapy in patients with advanced platinum-resistant ovarian cancer in a poster at the American Society of Clinical Oncology (ASCO) Meeting in Chicago, June 2-6, 2023.

• Zentalis Pharmaceuticals Reports Full Year 2022 Financial Results and Operational Updates

  3/1/2023

  ZentalisTM Pharmaceuticals, Inc. today announced financial results for the year ended December 31, 2022 and highlighted recent corporate accomplishments.

• Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - February 01, 2023

  2/1/2023

  Zentalis™ Pharmaceuticals, Inc. announced that on February 1, 2023, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 12,500 shares of the Company’s common stock to one newly hired employee.

• Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 03, 2023

  1/3/2023

  Zentalis™ Pharmaceuticals, Inc. announced that on January 3, 2023, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 30,625 shares of the Company’s common stock to two newly hired employees.

• Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  12/1/2022

  Zentalis TM Pharmaceuticals, Inc. today announced that on December 1, 2022, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 204,850 shares of the Company’s common stock to seven newly hired employees.

• Zentalis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Updates

  11/9/2022

  ZentalisTM Pharmaceuticals, Inc. today announced financial results for the third quarter ended September 30, 2022 and highlighted recent corporate accomplishments.

• Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 01, 2022

  11/1/2022

  Zentalis™ Pharmaceuticals, Inc. announced that on November 1, 2022, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 350,025 shares of the Company’s common stock to four newly hired employees.

• Zentalis Pharmaceuticals Announces First ZN-c3 Clinical Development Collaboration with Pfizer

  10/24/2022

  Zentalis™ Pharmaceuticals, Inc. today announced plans to initiate the first study of its collaboration with Pfizer on Zentalis’ product candidate ZN-c3, a selective Wee1 inhibitor designed to induce synthetic lethality in cancer cells.

• Zentalis Pharmaceuticals Appoints Dr. Mark Lackner as Chief Translational Officer, Head of Biomarker Strategy

  10/17/2022

  Zentalis™ Pharmaceuticals, Inc. today announced the appointment of Mark Lackner, PhD, as Chief Translational Officer, Head of Biomarker Strategy.

• Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 03, 2022

  10/3/2022

  Zentalis™ Pharmaceuticals, Inc. announced that on October 3, 2022, the Compensation Committee of Zentalis’ Board of Directors granted the following equity awards to Dr. Carrie Brownstein, who joined the Company as Chief Medical Officer.

• Zentalis Pharmaceuticals Promotes Co-Founder Kevin Bunker, Ph.D. to Chief Scientific Officer

  9/27/2022

  Zentalis™ Pharmaceuticals, Inc. today announced the promotion of co-founder Kevin Bunker, Ph.D., to Chief Scientific Officer.

• Zentalis Pharmaceuticals Appoints Dr. Carrie Brownstein as Chief Medical Officer

  9/19/2022

  Zentalis™ Pharmaceuticals, Inc. today announced the appointment of Carrie Brownstein, MD, as Chief Medical Officer (CMO), effective October 3, 2022.